お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
988626

細胞治療バイオマニュファクチャリング:世界市場

Cell Therapy Biomanufacturing: Global Markets

出版日: | 発行: BCC Research | ページ情報: 英文 112 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.25円
細胞治療バイオマニュファクチャリング:世界市場
出版日: 2021年02月11日
発行: BCC Research
ページ情報: 英文 112 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の細胞治療バイオマニュファクチャリング市場は、2020年の65億米ドルから、2025年までに102億米ドルに達し、2020年~2025年のCAGRで9.4%の成長が予測されています。

細胞治療バイオマニュファクチャリングにおける治療の種類は、2020年の36億米ドルから、2025年には54億米ドルに達し、2020年~2025年のCAGRで8.4%の成長が予測されています。

細胞治療バイオマニュファクチャリングにおける細胞源は、2020年の29億米ドルから、2025年には48億米ドルに達し、2020年~2025年のCAGRで10.6%の成長が予測されています。

当レポートでは、世界の細胞治療バイオマニュファクチャリング市場について調査分析し、主な市場分析、市場促進要因・抑制要因、競合発展、市場動向などについて、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 サマリーとハイライト

第3章 市場・技術の背景

  • 細胞治療バイオマニュファクチャリングの紹介
  • 細胞治療とは
  • 幹細胞移植
  • 自家
  • 同種異系
  • 同系
  • 幹細胞バイオマニュファクチャリングと分類
  • 差別化能力ベース
  • 供給源ベース
  • 細胞ベース治療技術の分類
  • 体細胞技術
  • 三次元技術
  • 細胞不死化技術
  • ゲノム編集技術
  • 細胞可塑性技術
  • ウイルスベクター技術を使用した細胞のex vivo遺伝子組み換え
  • ウイルスベクター技術を使用した細胞のin vivo遺伝子組み換え
  • 幹細胞の応用
  • 細胞治療のメカニズム
  • 細胞ベース治療の提供方法
  • 細胞治療モデルの製造
  • 委託製造業者の役割
  • 進行中の臨床試験
  • 幹細胞治療に焦点を当てた臨床試験ネットワーク

第4章 市場動向と課題

  • 課題
  • 促進要因
  • 抑制要因
  • 機会

第5章 市場内訳:製品タイプ別

  • 治療の種類
  • 細胞源
  • キメラ抗原受容体(CAR)T細胞治療の需要の急増

第6章 市場内訳:応用別

  • 心血管疾患
  • 微粒子細胞の模倣
  • 骨の修復
  • 神経学的障害
  • 脊髄損傷
  • 脳卒中
  • パーキンソン病
  • 筋萎縮性側索硬化症
  • 多発性硬化症
  • 脳性麻痺
  • アルツハイマー病
  • 視力回復
  • 脊椎の修復
  • バッテン病
  • 骨格筋の修復
  • 本質的な治癒メカニズム
  • 細胞治療のメカニズム
  • がん
  • その他の疾患

第7章 市場内訳:地域別

  • 市場概要
  • 北米
  • 米国
  • カナダ
  • メキシコ
  • 欧州
  • 欧州の心血管疾患
  • 心血管疾患(CVD)の要因
  • ドイツ
  • 英国
  • フランス
  • アジア太平洋地域
  • 中国
  • インド
  • 日本
  • その他のアジア太平洋地域
  • その他の世界の地域
  • 南米
  • 中東・アフリカ

第8章 規制構造

  • FDAの承認
  • CBER規制に対する細胞治療
  • 連邦規則集
  • 細胞収集
  • 規制コード
  • 幹細胞治療の使用を管理する法律
  • EUによる規制状況の決定
  • インドの規制シナリオ

第9章 企業プロファイル

  • BONE THERAPEUTICS SA
  • BRISTOL-MYERS SQUIBB CO.
  • CALADRIUS BIOSCIENCES INC.
  • CELL THERAPIES PTY LTD.
  • CELLULAR BIOMEDICINE GROUP INC.
  • IOVANCE BIOTHERAPEUTICS INC.
  • LONZA GROUP LTD.
  • MERCK KGAA
  • NEUROGENERATION INC.
  • NOVARTIS AG
  • REGEN BIOPHARMA INC.
  • REGENEUS LTD.

第10章 付録:参考資料

図表

List of Tables

  • Summary Table : Global Market for Cell Therapy Biomanufacturing, by Product Type, Through 2025
  • Table 1 : Types of Stem Cells
  • Table 2 : Global Market for Cell Therapy Biomanufacturing, by Type of Therapy, Through 2025
  • Table 3 : Global Market for Cell Therapy Biomanufacturing, by Source of Cells, Through 2025
  • Table 4 : Global Market for Cell Therapy Biomanufacturing, by Application, Through 2025
  • Table 5 : Treatments for Cardiovascular Diseases
  • Table 6 : Global Market for Cell Therapy Biomanufacturing for Cardiovascular Disease Applications, Through 2025
  • Table 7 : Global Market for Cell Therapy Biomanufacturing for Bone Repair Applications, Through 2025
  • Table 8 : Global Market for Cell Therapy Biomanufacturing for Neurological Disorder Applications, Through 2025
  • Table 9 : Global Market for Cell Therapy Biomanufacturing for Skeletal Muscle Repair Applications, Through 2025
  • Table 10 : Global Market for Cell Therapy Biomanufacturing for Cancer Treatment Applications, Through 2025
  • Table 11 : Global Market for Cell Therapy Biomanufacturing for Other Applications, Through 2025
  • Table 12 : North American Market for Cell Therapy Biomanufacturing, by Country, Through 2025
  • Table 13 : European Market for Cell Therapy Biomanufacturing, by Country, Through 2025
  • Table 14 : Asia-Pacific Market for Cell Therapy Biomanufacturing, by Country, Through 2025
  • Table 15 : Stem Cell Treatment Provided in Australia
  • Table 16 : Bone Therapeutics: Products
  • Table 17 : Bristol-Myers Squibb: Net Revenue, 2017-2019
  • Table 18 : Caladrius Biosciences: Products
  • Table 19 : Iovance Biotherapeutics: Products
  • Table 20 : Merck KGaA: Products
  • Table 21 : Regen BioPharma: Products
  • Table 22 : Regeneus: Products

List of Figures

  • Summary Figure : Global Market for Cell Therapy Biomanufacturing, by Product Type, 2019-2025
  • Figure 1 : Combination of Stem Cells and Biomaterials
  • Figure 2 : Global Market for Cell Therapy Biomanufacturing Market, by Product Type, 2019-2025
  • Figure 3 : Autologous and Allogeneic Cell Therapy Based on Source
  • Figure 4 : Mechanism of Bone Marrow
  • Figure 5 : Global Market for Cell Therapy Biomanufacturing, by Region, 2019-2025
  • Figure 6 : Global Market Share for Cell Therapy Biomanufacturing, by Region, 2025
  • Figure 7 : North American Market for Cell Therapy Biomanufacturing, 2019-2025
  • Figure 8 : North American Market Share for Cell Therapy Biomanufacturing, by Country, 2019
  • Figure 9 : European Market for Cell Therapy Biomanufacturing, 2019-2025
  • Figure 10 : European Market Share for Cell Therapy Biomanufacturing, by Country, 2019
  • Figure 11 : Asia-Pacific Market for Cell Therapy Biomanufacturing, 2019-2025
  • Figure 12 : Asia-Pacific Market Share for Cell Therapy Biomanufacturing, by Country, 2019
  • Figure 13 : South American Market for Cell Therapy Biomanufacturing, 2019-2025
  • Figure 14 : Middle Eastern and African Market for Cell Therapy Biomanufacturing, 2019-2025
目次
Product Code: BIO211A

Highlights:

The global market for cell therapy biomanufacturing should grow from $6.5 billion in 2020 to $10.2 billion by 2025, at compound annual growth rate (CAGR) of 9.4% for the period of 2020-2025.

The type of therapy for cell therapy biomanufacturing should grow from $3.6 billion in 2020 to $5.4 billion by 2025, at a CAGR of 8.4% for the period of 2020-2025.

The source of cells for cell therapy biomanufacturing should grow from $2.9 billion in 2020 to $4.8 billion by 2025, at a CAGR of 10.6% for the period of 2020-2025.

Report Scope:

This research report presents an in-depth analysis of the global cell therapy biomanufacturing market by product type, application and region. The report discusses the key inhibitors to the growth of cell therapy biomanufacturing. The report discusses the role of participants in the supply chain from manufacturers to researchers. The report analyzes key companies operating in the global cell therapy biomanufacturing market. In-depth patent analysis in the report will provide a look at the existing and coming technological trends.

In this report, the cell therapy biomanufacturing market is segmented by product type, application and region. Based on product type, the market is segmented into source of cells (T-cells, Dendritic cells, tumor cells and stem cells), and type of therapy (autologous cell therapies, allogeneic cell therapies). The market by application is categorized into cardiovascular diseases, bone repair, neurological disorders, skeletal muscle repair, cancer and others. The market by region is segmented into North America, Europe, Asia-Pacific and ROW.

Report Includes:

  • 23 tables
  • An overview of the global markets for cell therapy biomanufacturing
  • Estimation of the market size and analyses of global market trends with data from 2019, 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Assessment of market dynamics such as drivers, restraints, opportunities, and identification of growth inhibiting areas that affect the global market
  • Detailed description of allogeneic (third party donor cells) and autologous (one's own body cells) forms of cell therapy and analysis of its advantages and limitations
  • Information on clinical trials of cell therapies; insights into regulatory scenarios and initiatives by government organization
  • Evaluation of current market trends, market size, market forecast, and technological advancements within the industry
  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies; and a relevant patent analysis
  • Company profiles of major players of the industry, including Bristol-Myers Squibb Co., Caladrius Biosciences Inc., Lonza Group Ltd., Merck KGaA and Novartis AG

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Methodology
  • Market Estimates
  • Information Sources
  • Primary Research
  • Secondary Research
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

  • Introduction

Chapter 3 Market and Technology Background

  • Introduction to Cell Therapy Biomanufacturing
  • What is Cell Therapy?
  • Stem Cell Transplantation
  • Autologous
  • Allogeneic
  • Syngeneic
  • Stem Cell Biomanufacturing and Classification
  • Based on Ability to Differentiate
  • Based on Source
  • Classification of Cell-Based Therapy Technology
  • Somatic Cell Technologies
  • Three-Dimensional Technologies
  • Cell Immortalization Technologies
  • Genome Editing Technologies
  • Cell Plasticity Technologies
  • Ex vivo Gene Modification of Cells Using Viral Vector Technologies
  • In vivo Gene Modification of Cells Using Viral Vector Technologies
  • Stem Cell Applications
  • Mechanism of Cell Therapy
  • Delivery Method of Cell-Based Therapy
  • Manufacturing Cell Therapy Models
  • Role of Contract Manufacturers
  • Ongoing Clinical Trials
  • Clinical Trial Network Focused on Stem Cell Treatments

Chapter 4 Market Trends and Challenges

  • Challenges
  • Drivers
  • Restraints
  • Opportunity

Chapter 5 Market Breakdown by Product Type

  • Type of Therapy
  • Source of Cells
  • Rise in the Demand for Chimeric Antigen Receptor (CAR) T Cell Therapy

Chapter 6 Market Breakdown by Application

  • Cardiovascular Disease
  • Microparticles Cell Imitation
  • Bone Repair
  • Neurological Disorders
  • Spinal Cord Injury
  • Stroke
  • Parkinson's Disease
  • Amyotrophic Lateral Sclerosis
  • Multiple Sclerosis
  • Cerebral Palsy
  • Alzheimer's Disease
  • Vision Restoration
  • Vertebral Repair
  • Batten's Disease
  • Skeletal Muscle Repair
  • Intrinsic Healing Mechanisms
  • Cell Therapy Mechanism
  • Cancer
  • Other Diseases

Chapter 7 Market Breakdown by Region

  • Market Overview
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Cardiovascular Diseases in Europe
  • Contributing Factors for Cardiovascular Diseases (CVD)
  • Germany
  • U.K.
  • France
  • Asia-Pacific
  • China
  • India
  • Japan
  • Rest of APAC
  • Rest of the World
  • South America
  • Middle East and Africa

Chapter 8 Regulatory Structure

  • FDA Approvals
  • Cell Therapy for CBER Regulations
  • Federal Regulation codes
  • Collection of Cells
  • Code of Regulation
  • Legislation Governing Use of Stem Cell Treatments
  • EU Determination of Regulatory Status
  • Regulatory Scenario in India

Chapter 9 Company Profiles

  • BONE THERAPEUTICS SA
  • BRISTOL-MYERS SQUIBB CO.
  • CALADRIUS BIOSCIENCES INC.
  • CELL THERAPIES PTY LTD.
  • CELLULAR BIOMEDICINE GROUP INC.
  • IOVANCE BIOTHERAPEUTICS INC.
  • LONZA GROUP LTD.
  • MERCK KGAA
  • NEUROGENERATION INC.
  • NOVARTIS AG
  • REGEN BIOPHARMA INC.
  • REGENEUS LTD.

Chapter 10 Appendix: References

  • Sources
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.